Premium
Targeted radionuclide therapy in head and neck cancer
Author(s) -
Nestor Marika V.
Publication year - 2010
Publication title -
head and neck
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.012
H-Index - 127
eISSN - 1097-0347
pISSN - 1043-3074
DOI - 10.1002/hed.21243
Subject(s) - head and neck cancer , medicine , targeted therapy , monoclonal antibody , cancer , head and neck , cancer therapy , oncology , radioimmunotherapy , rational design , radiation therapy , cancer research , immunology , antibody , surgery , biology , genetics
Abstract There is great potential for targeted radionuclide therapy (TRT) in the treatment of head and neck cancer. In recent years, developments in fields such as antigen screening, protein engineering, and cancer biology have facilitated the rational design of targeted pharmaceuticals, with monoclonal antibodies forming the most rapidly expanding category. TRT may be a promising way to improve targeted treatment, especially in head and neck cancer, because of the intrinsic radiosensitivity of this tumor type. TRT may also provide a good foundation on which to build rational biologic combination therapies. In the next few years the use of TRT may offer new opportunities for further improvement of the therapeutic ratio that potentially may obviate or reduce the need for conventional cytotoxics. © 2009 Wiley Periodicals, Inc. Head Neck, 2010